Stem Cells and Cell Therapies in Lung Biology and Diseases

描述（由申请人提供）：肺生物学和疾病中的干细胞和细胞疗法 利用干细胞修复和再生病变肺是一种令人兴奋的潜在治疗多种肺部疾病的方法。 越来越多的信息表明，通常不驻留在肺中的细胞可用于损害肺损伤，也可用于诱导损伤后的修复和重塑。与此同时，生物工程研究也在激增，研究使用人工和去细胞化的肺基质作为三维肺再生的框架。 这些研究与利用干细胞和/或细胞疗法的研究相结合是一个有前途和快速发展的方向。 这些研究已经进一步证实了对驻留在肺中的干细胞和/或祖细胞参与肺发育以及肺损伤后修复和重塑的分子和细胞事件的理解的显著增加。 我们在佛蒙特大学举办了四次会议：2005年7月，由NHBLI和囊性纤维化基金会赞助的“成人干细胞，肺生物学和肺部疾病”，以及2007年7月，2009年和2011年7月的“干细胞和细胞疗法在肺生物学和疾病中”，多年来，NHLBI通过R13会议拨款以及Alpha 1抗胰蛋白酶基金会，埃默里呼吸健康中心，LAM治疗联盟，肺纤维化基金会和佛蒙特大学医学院赞助。 这些会议汇集了相关的领先国际调查人员以及感兴趣的初级教师和学员进行辩论和讨论 在这个快速发展的领域。这些会议都非常成功，既刺激了该领域的研究，又产生了一系列基础研究和翻译研究的指导方针，供研究人员和资助机构使用。 随着干细胞和细胞治疗肺部疾病的研究继续快速发展，我们建议再次召集相关研究人员以及NHLBI，FDA和非营利呼吸系统疾病基金会的代表再次辩论和讨论当前的问题。 需要特别讨论的一个领域是基础研究和转化研究之间的平衡以及临床试验的作用，特别是现在已经有了干细胞治疗肺动脉高压和COPD的临床试验。 即将举行的会议的一个特别重点将是不断上升的初级调查员和受训人员，一个新的特点将是一个专门发展这一领域的职业生涯的会议。 与往常一样，Junor研究员和实习生（研究生，博士后，研究员）将特别有针对性地纳入会议讨论以及海报会议。 作为一个持续的特点，学员将能够根据对海报摘要的盲态审查来竞争更多的旅行奖励。 会议计划于2013年7月在佛蒙特大学举行。 潜在参与者的热情很高。 我们预计，这次会议将再次促进广泛的讨论和辩论，并将显着指导方向的基础和临床研究的干细胞和细胞疗法的肺部疾病。

DESCRIPTION (provided by applicant): Stem Cells and Cell Therapies in Lung Biology and Diseases Repair and regeneration of diseased lung with stem cells is an exciting potential therapeutic approach for a variety of lung diseases. Increasing information suggests that cells normally not resident in the lung can be utilized to impair lung injry and also to induce repair and remodeling after injury. In parallel, there has been a surge in bioengineering studies investigating use of artificial and de-cellularized lung matrices as framework for three-dimensional lung regeneration. The combination of these studies with those utilizing stem cells and/or cell therapies is a promising and rapidly developing direction. These studies have been further paralleled by significant increases in understanding the molecular and cellular events by which stem and/or progenitor cells resident in the lung participate in both lung development and in repair and remodeling after lung injury. We have held four previous conferences at the University of Vermont: July 2005, "Adult Stem Cells, Lung Biology, and Lung Disease", sponsored by the NHBLI and Cystic Fibrosis Foundation~ and in July 2007, 2009, and 2011 "Stem Cells and Cell Therapies in Lung Biology and Disease", sponsored through the years by the NHLBI through an R13 conference grant as well as by the Alpha 1 Antitrypsin Foundation, Emory Center for Respiratory Health, LAM Treatment Alliance, Pulmonary Fibrosis Foundation, and the University of Vermont College of Medicine. These conferences have that brought together relevant leading international investigators as well as interested junior faculty and trainees to debate and discuss issues in this rapidly moving field. These conferences have been highly successful and have both stimulated the field and resulted in a series of guidelines for basic and translation research to be utilized by both investigators and by funding agencies. As studies of stem cell and cell therapies for lung diseases continues to move at a rapid pace, we propose to again convene the relevant investigators as well as representatives from the NHLBI, FDA, and non-profit Respiratory Disease Foundations to again debate and discuss current issues. One area in particular to be discussed is the balance between basic and translational research and the role of clinical trials, particularly as there have now been clinica trials of stem cells for pulmonary hypertension and for COPD. A particular focus for the upcoming conference will be on rising junior investigators and trainees and a new feature will be a session devoted to developing careers in this area. As always, junor investigators and trainees (graduate, post-doctoral, fellow) will be particularly targeted for inclusion in both conference discussions as well as in poster sessions. As a continuing feature, trainees will be able to compete for an increased number of travel awards based on blinded review of poster abstracts. The conference is planned for July 2013 at the University of Vermont. Enthusiasm is high among potential participants. We anticipate that this conference will again foster extensive discussion and debate and will significantly guide directions in basic and clinical research of stem cells and cell therapies for lung diseases.